Phaseline

Companies › BioInvent International

BioInvent International: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BI-1910
unclear - mechanism not stated in registry
–Phase 1Solid TumorsJul 2027
BI-1607
FAP inhibitor (fibroblast activation protein inhibitor)
FAPPhase 1Melanoma MetastaticJul 2027
BI-1206
anti-CD32B monoclonal antibody
FCGR2BPhase 1Indolent B-Cell Non-Hodgkin Lymphoma; Solid Tumor, AdultSep 2027
BI-1808
TNFRSF14 (HVEM) agonist
–Phase 1Advanced MalignanciesJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06205706BI-1910Phase 1Solid TumorsOncologyJul 2027
NCT06784648BI-1607Phase 1Melanoma MetastaticOncologyJul 2027
NCT03571568BI-1206Phase 1Indolent B-Cell Non-Hodgkin LymphomaOncologySep 2027
NCT04219254BI-1206Phase 1Solid Tumor, AdultOncologyNov 2027
NCT04752826BI-1808Phase 1Advanced MalignanciesOncologyJan 2028

Targets

FCGR2B (1) FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics argenx Nuvig Therapeutics Zenas BioPharma (USA) Novartis Ratio Therapeutics Beijing Biotech SOFIE

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.